Brainify.AI

We are proud to share our latest publication on Nature.com, where we explore the use of EEG biomarkers in precision psychiatry. Our paper details the innovative approaches we employ, focusing on the intersection of advanced technology and strategic business applications. In this research, we highlight how our AI-driven solutions, combined with EEG data, can optimize psychiatric treatment outcomes and reduce placebo responses in clinical trials. This work is a major step forward in our mission to revolutionize mental healthcare. 🔗 Check out the full article here: https://lnkd.in/eVzCqrPB

Today, our CEO Mariam Khayretdinova Khayretdinova will present at the prestigious D44 Spring Neuropsychiatry Investor Reception in New York City. 🎤 The event will feature an opening speech by the distinguished Dr. Jeffrey Lieberman, a leading figure in psychiatry and a former president of the American Psychiatric Association. 🧠 Join us as Mariam shares Brainify.AI’s groundbreaking advancements and our vision for the future of neuropsychiatry. 🚀 Stay tuned for insights and updates from this landmark event. Together, we’re shaping the future of mental health. #BrainifyAI #Neuropsychiatry #Innovation #Healthcare

Brainify.Ai is excited to announce our sponsorship of The 4th Annual Psychedelic Therapeutics & Drug Development conference. We look forward to reconnecting with old partners and establishing new collaborations at this event! #sponsorship #conference #networking

Brainify.AI today at Financial Times US Pharma and Biotech Summit. Ivan Mishanin is attending to meet existing and potencial partners. #FTPharma

Brainify.AI is happy to be sponsoring the 4th Annual Psychedelic Therapeutics & Drug Development Conference (https://lnkd.in/g5qk2AeY) on May 23-24, 2024 in Boston. I hope you can join us at this year's event. #psychedelics #psychedelicresearch #psychedelictherapy

Brainify.AI, a pioneering company at the forefront of AI precision psychiatry, today announced the appointment of Dr. Jim Doherty to its advisory board. Dr. Doherty currently serves as the President and Chief Development Officer at Acumen Pharmaceuticals, where his extensive experience in central nervous system (CNS) research and development has significantly advanced the field. Dr. Doherty was pivotal at Sage Therapeutics as the Chief Development Officer, where he led numerous groundbreaking projects focused on novel CNS disorder treatments. His efforts were instrumental in the development of key pharmaceuticals like Zulresso and Zurzuvae, which have made significant impacts in their respective areas. Prior to his tenure at Sage, Dr. Doherty spearheaded the preclinical Neuroscience department at AstraZeneca Pharmaceuticals within the CNS and Pain Innovative Medicine unit. His leadership there resulted in over 20 programs transitioning from preclinical stages to clinical development, showcasing his ability to drive projects from conception to fruition. Throughout his career, Dr. Doherty has been a formidable presence in neurology, psychiatry, analgesia, seizure control, and cognition research, contributing to the field with over 250 peer-reviewed scientific publications, abstracts, and presentations. Additionally, his innovative work has earned him numerous patents. With Dr. Doherty on board, Brainify.AI is poised to enhance its advisory team, ensuring that the company remains at the cutting edge of AI-driven neuroscience solutions. His background will be particularly beneficial in guiding Brainify.AI through its next phase of growth as it seeks to develop new technologies and therapies that address the complexities of the human brain. Dr. Doherty's leadership and expertise are expected to drive significant advancements in Brainify.AI's research initiatives and product development, providing fresh insights and a strategic direction that will benefit the company and the broader scientific community.

Mark Your Calendars! 🗓️ Mariam Khayretdinova, the visionary CEO & co-founder of Brainify.AI, is gearing up to unveil groundbreaking insights at the Forging the Future of Business with AI conference. Join us at MIT Media Lab on April 18th to dive deep into the latest advancements in precision psychiatry. This session is a must for anyone passionate about the intersection of AI and mental health! Why this matters: The insights Mariam will share are not just transformative for the field but essential for anyone looking to stay ahead in the rapidly evolving landscape of technology in healthcare. 🔗 https://lnkd.in/ekURy4xJ Excited? Hit 'Like' and share this post to spread the word! Your network will thank you! 💡#PrecisionPsychiatry #AIinHealthcare #MITMediaLab #FutureofAI #MentalHealthInnovation #BrainifyAI #TechConference #DigitalHealth #InnovativeLeadership

We are thrilled to announce that our CEO, Mariam Khayretdinova, will be one of the six entrepreneurs pitching at the prestigious Harvard Business School Healthcare Alumni Association Startup Showcase. This event, in partnership with the HBS Alumni Angels of Greater NY, highlights innovative life sciences startups founded by Harvard alumni. Join us this Thursday to support Mariam as she presents our groundbreaking solutions designed to transform the healthcare industry. Don’t miss this incredible opportunity to see pioneering ideas in action and learn more about the future of healthcare innovation. 📅 Date: April 18, 2024 🕒 Time: 6 PM EST 📍 Location: Online – Register HERE (https://lnkd.in/eK9QcW-v) to witness groundbreaking innovation. Let’s cheer on Mariam as she takes the stage to represent Brainify.AI! #Innovation #Healthcare #StartupShowcase #HBSAlumni

In the realm of psychiatric clinical trials, a silent issue often dictates the boundary between groundbreaking discoveries and missed opportunities. It's the concept of **statistical power**—a crucial yet frequently overlooked aspect, especially in studies addressing depression. 🔍 Why do so many trials in psychiatry, especially those targeting depression, fail to deliver conclusive results? The crux of the matter lies in being underpowered. An underpowered study lacks the necessary precision to detect the true effect of the treatment, if there is one. This is akin to searching for a needle in a haystack with a magnet too weak to attract the needle—resulting in trials that conclude with uncertainty, unable to confirm the efficacy of potentially life-changing treatments. ✨ The Importance of Powering Up Elevating the statistical power of a study isn't merely a technical adjustment; it's a pivotal shift towards more ethical, effective, and meaningful research. By ensuring our trials are properly powered, we: - Maximize the utilization of resources: Every participant's time and every research dollar count. Adequately powered studies respect both. - Enhance the reliability of findings: We owe it to patients and practitioners to provide clear, actionable insights, not ambiguous results. - Accelerate progress in mental health treatments: With depression affecting millions globally, every bit of clarity and every validated treatment can be a beacon of hope. As we venture further into understanding and treating psychiatric conditions, let's prioritize the foundational elements that make our research robust. Let's not just aim for more trials but for more powerful, insightful, and impactful studies. Because at the end of the day, it's not just about the data we collect, but about the lives we aim to improve. #Psychiatry #ClinicalTrials #MentalHealthResearch #StatisticalPower #DepressionTreatment

Thrilled to share that our CEO, Mariam Khayretdinova, represented Brainify.AI at the World Economic Forum in Davos, participating in a groundbreaking panel discussion on the fusion of artificial intelligence and psychiatry. This discussion, focusing on depression, delved into how AI and biological data, like EEG, are revolutionizing drug discovery and predicting treatment responses. Key takeaways from Miriam’s contribution: • Innovative AI Applications: Mariam highlighted how AI algorithms, including our own PlaceboInsight AI, are transforming psychiatry, making treatment more personalized and efficient. • Enhancing Drug Discovery: She emphasized AI’s role in identifying potential compounds for depression treatment, accelerating the path from lab to patient. • Clinical Trial Efficiency: Mariam discussed how AI refines patient selection, especially in identifying placebo responders, thereby enhancing the accuracy and reliability of clinical trials. • Ethical AI Use: She also touched on the importance of ethical considerations and transparency in AI, ensuring patient data privacy and trust in AI-driven treatments. Mariam’s insights reflect our commitment at Brainify.AI to advance mental health treatment through AI and ML. Stay tuned for more updates as we continue to innovate at the intersection of technology and healthcare. #WorldEconomicForum #ArtificialIntelligence #Psychiatry #MentalHealth #Innovation #BrainifyAI